Catalog Home Page

Abacavir hypersensitivity.

Nolan, D., Almeida, C. and Phillips, E. (2007) Abacavir hypersensitivity. In: Pichler, Werner J., (ed.) Drug Hypersensitivity. S.Karger AG, Basel, Switzerland.

Google Books Preview: https://books.google.com.au/books?hl=en&lr=&id=S9I...
*Open access. Some pages may not be available

Abstract

Abacavir is a commonly prescribed HIV drug belonging to the nucleoside revers transcriptase inhibitor (NRTI) class. The major treatment-limiting side effect associated with its use is an early onset multi-system drug hypersensitivity reaction typically including some combination of rash, fever and gastrointestinal symptoms, occurring within 6 weeks of initiating treatment in approximately 5-8% of abacavir recipients. Susceptibility to this drug hypersensitivity syndrome is strongly predicated by the presence of a specific human leukocyte antigen *HLA) allele - HLA-B*5701 - which represents the dominant risk factor for abacavir hypersensitivity among Caucasian and Hispanic populations. The frequency distribution of this genetic marker in different populations is likely to provide a rational basis for racially-defined differences in susceptibility, while the critical role of HLA-B*5701 in directing CD8+ T-cell-dependent, HLA-restricted immune responses provides a key role for this genetic variant in the pathogenesis of abacavir-specific immune responses. In this chapter, we review the implications of the genetic association for clinical practice as well as a current knowledge of its immunological basis

Publication Type: Book Chapter
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Publisher: S.Karger AG
URI: http://researchrepository.murdoch.edu.au/id/eprint/37358
Item Control Page Item Control Page